Alkem signs agreement with US-based Sonnet BioTherapeutics to develop, commercialise its drug candidate for diabetic peripheral neuropathy in India
Express Pharma
OCTOBER 10, 2024
Alkem Laboratories, has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings to develop, manufacture and commercialise the drug candidate SON-080 for the treatment of diabetic peripheral neuropathy in India. Diabetic peripheral neuropathy primarily affects the hands and lower limbs. “SON-080”
Let's personalize your content